



**For Immediate Release**

**March 7, 2022**

## **Acuitas Therapeutics Donates \$50,000 to Support Humanitarian Efforts in Ukraine**

**Vancouver, B.C.** – Acuitas Therapeutics, a Vancouver-based, private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles, has donated \$50,000 to the [Canadian Red Cross](#) to support that organization’s humanitarian efforts in Ukraine, President and CEO, Dr. Thomas Madden announced today.

Said Dr. Madden: “The unprovoked invasion of Ukraine by Russia has created a humanitarian crisis: supply chains are disrupted or destroyed, food is scarce, and people are fleeing their homes as the lives that they had just a few short weeks ago have been ripped apart. We wanted to contribute to help ease some of the human suffering.” He added, “Acuitas stands with the people of Ukraine. We must do what we can to support those who are under attack. Every act of support and each donation helps to show that Canada, and the world, are with them.”

Donations to the Canadian Red Cross allow them to “respond to humanitarian needs generated by almost eight years of conflict, as well as preparedness and response efforts due to heightened tensions in Ukraine. The support could include preparedness, immediate and ongoing relief efforts, long-term recovery, resiliency, and other critical humanitarian activities as needs arise, both in Ukraine and surrounding countries, including supporting populations displaced.”

### **About Acuitas Therapeutics**

Founded in February 2009, Vancouver-based Acuitas Therapeutics ([www.acuitastx.com](http://www.acuitastx.com)) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY<sup>®</sup>, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries.

-END-